PMID- 30706372
OWN - NLM
STAT- MEDLINE
DCOM- 20200814
LR  - 20211112
IS  - 1724-6059 (Electronic)
IS  - 1121-8428 (Linking)
VI  - 32
IP  - 3
DP  - 2019 Jun
TI  - C-reactive protein velocity and the risk of acute kidney injury among ST 
      elevation myocardial infarction patients undergoing primary percutaneous 
      intervention.
PG  - 437-443
LID - 10.1007/s40620-019-00594-2 [doi]
AB  - BACKGROUND: Elevated C-reactive protein (CRP) was shown to be associated with an 
      increased risk for acute kidney injury (AKI) in ST elevation myocardial 
      infarction (STEMI) patients undergoing primary percutaneous coronary intervention 
      (PCI), however, the optimal time frame to measure CRP for risk stratification is 
      not known. We evaluated the relation between the change in CRP over time (CRP 
      velocity-CRPv) and AKI among STEMI patients treated with primary PCI. METHODS: We 
      included 801 STEMI who presented between 2007 and 2017 and had their CRP measured 
      with a wide range assay (wr-CRP) at least twice during the 24 h after admission. 
      CRPv was defined as the change in wr-CRP concentration (mg/l) divided by the 
      change in time (in h) between the two measurements. Patient's medical records 
      were reviewed for occurrence of AKI. RESULTS: Mean age was 62 +/- 16 and 80% were 
      males. Patients with AKI had significantly higher CRPv (1.47 versus 0.4 mg/l/h, 
      p < 0.001). In a multivariate regression model CRPv was independently associated 
      with AKI (OR 1.03, 95% CI 1.01-1.0 5, p = 0.001). On receiver operating 
      characteristic (ROC) curve the optimal cutoff value of CRPv to predict AKI was 
      measured as more than 0.8 mg/l/h, with 70% sensitivity and 65% specificity (AUC 
      0.712, 95% CI 0.64-0.78, p < 0.001). CONCLUSION: CRPv might be an independent and 
      rapidly measurable biomarker for AKI following primary PCI in STEMI patients.
FAU - Zahler, David
AU  - Zahler D
AD  - Department of Cardiology, Tel-Aviv Sourasky Medical Center, Sackler Faculty of 
      Medicine, Tel-Aviv University, 6 Weizman St, Tel Aviv, 64239, Israel.
FAU - Rozenfeld, Keren-Lee
AU  - Rozenfeld KL
AD  - Department of Cardiology, Tel-Aviv Sourasky Medical Center, Sackler Faculty of 
      Medicine, Tel-Aviv University, 6 Weizman St, Tel Aviv, 64239, Israel.
FAU - Stein, Maya
AU  - Stein M
AD  - Department of Cardiology, Tel-Aviv Sourasky Medical Center, Sackler Faculty of 
      Medicine, Tel-Aviv University, 6 Weizman St, Tel Aviv, 64239, Israel.
FAU - Milwidsky, Assi
AU  - Milwidsky A
AD  - Department of Cardiology, Tel-Aviv Sourasky Medical Center, Sackler Faculty of 
      Medicine, Tel-Aviv University, 6 Weizman St, Tel Aviv, 64239, Israel.
FAU - Berliner, Shlomo
AU  - Berliner S
AD  - Department of Cardiology, Tel-Aviv Sourasky Medical Center, Sackler Faculty of 
      Medicine, Tel-Aviv University, 6 Weizman St, Tel Aviv, 64239, Israel.
FAU - Banai, Shmuel
AU  - Banai S
AD  - Department of Cardiology, Tel-Aviv Sourasky Medical Center, Sackler Faculty of 
      Medicine, Tel-Aviv University, 6 Weizman St, Tel Aviv, 64239, Israel.
FAU - Arbel, Yaron
AU  - Arbel Y
AD  - Department of Cardiology, Tel-Aviv Sourasky Medical Center, Sackler Faculty of 
      Medicine, Tel-Aviv University, 6 Weizman St, Tel Aviv, 64239, Israel.
FAU - Shacham, Yacov
AU  - Shacham Y
AUID- ORCID: 0000-0003-0805-3185
AD  - Department of Cardiology, Tel-Aviv Sourasky Medical Center, Sackler Faculty of 
      Medicine, Tel-Aviv University, 6 Weizman St, Tel Aviv, 64239, Israel. 
      Kobyshacham@gmail.com.
LA  - eng
PT  - Journal Article
PT  - Observational Study
DEP - 20190131
PL  - Italy
TA  - J Nephrol
JT  - Journal of nephrology
JID - 9012268
RN  - 0 (Biomarkers)
RN  - 9007-41-4 (C-Reactive Protein)
RN  - AYI8EX34EU (Creatinine)
SB  - IM
MH  - Acute Kidney Injury/blood/*etiology
MH  - Aged
MH  - Biomarkers/blood
MH  - C-Reactive Protein/*metabolism
MH  - Creatinine/blood
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Percutaneous Coronary Intervention/*adverse effects
MH  - Prognosis
MH  - ROC Curve
MH  - Retrospective Studies
MH  - Risk Factors
MH  - ST Elevation Myocardial Infarction/blood/complications/*surgery
MH  - Severity of Illness Index
OTO - NOTNLM
OT  - Acute kidney injury
OT  - Acute myocardial infarction
OT  - Biomarkers
OT  - C-reactive protein
EDAT- 2019/02/02 06:00
MHDA- 2020/08/15 06:00
CRDT- 2019/02/02 06:00
PHST- 2018/11/05 00:00 [received]
PHST- 2019/01/28 00:00 [accepted]
PHST- 2019/02/02 06:00 [pubmed]
PHST- 2020/08/15 06:00 [medline]
PHST- 2019/02/02 06:00 [entrez]
AID - 10.1007/s40620-019-00594-2 [pii]
AID - 10.1007/s40620-019-00594-2 [doi]
PST - ppublish
SO  - J Nephrol. 2019 Jun;32(3):437-443. doi: 10.1007/s40620-019-00594-2. Epub 2019 Jan 
      31.